ROCKVILLE, Md., Sept. 10, 2007 (PRIME NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF) today announced that remarks submitted during the public comment period of the National Coverage Assessment (NCA) for Platelet Rich Plasma (PRP) gel by the Centers for Medicare and Medicaid Services (CMS) were overwhelmingly positive.
